Epidermal growth factor receptor (EGFR), a critical factor promotes lung cancer cell
proliferation and survival. Knockdown of EGFR expression thus promise beating lung cancer …

Background Systemic inflammatory response (SIR) may influence prognosis in epidermal
growth factor receptor (EGFR)-mutated (m) non–small-cell lung cancer (NSCLC) …

Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) have shown
promise against non-small cell lung cancers (NSCLCs) in clinics but the utility is often short …

Background: Outcome of patients with advanced non-small cell lung cancer (NSCLC)
treated with platinum-based doublet chemotherapy is usually poor, with overall survival …

Purpose A substantial fraction of all non-small cell lung cancers (NSCLC) carry a mutation in
the EGFR gene for which an effective treatment with anti-tyrosine kinases (TKIs) is available …

Interventions: Four cycles of carboplatin and docetaxel chemotherapy reduced the size of
the tumor; however, it increased in size after 8 months, and re-challenge chemotherapy (RC) …

Results: The DNA extraction amount of the smear was 2.6 to 258.8 ng/μL, and that of the cell
block was 1.4 to 139.9 ng/μL. The DNA quantity and purity of DNA extracts isolated from …

Tyrosine kinase inhibitors (TKIs) of the epidermal growth factor receptor (EGFR) may
achieve long-term survival in selected cases with advanced non-small cell lung cancer …

Stereotactic radiosurgery (SRS) using the Gamma Knife (GK) is now being increasingly
utilized for the treatment of brain metastases. However, there are a few reported cases of …

The prognosis of advanced non-small cell lung cancer (NSCLC) has significantly improved
for certain patients with the development of epidermal growth factor receptor tyrosine kinase …